Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent HER2-Positive Breast Carcinoma”

215 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 215 results

Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Early research (Phase 1)Study completedNCT00068757
What this trial is testing

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Who this might be right for
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC 23
Early research (Phase 1)Study completedNCT05301530
What this trial is testing

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Who this might be right for
Breast Cancer MetastaticBreast Cancer FemaleBreast Cancer Recurrent
Nanogen Pharmaceutical Biotechnology Joint Stock Company 50
Large-scale testing (Phase 3)Active Not RecruitingNCT06057610
What this trial is testing

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-PositiveRecurrent or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 868
Testing effectiveness (Phase 2)Active Not RecruitingNCT03384914
What this trial is testing

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer FemaleBreast Cancer, MaleBreast Cancer Stage I+5 more
H. Lee Moffitt Cancer Center and Research Institute 119
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Early research (Phase 1)Study completedNCT02060253
What this trial is testing

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 9
Not applicableLooking for participantsNCT06358625
What this trial is testing

Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Center Eugene Marquis 120
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Early research (Phase 1)Study completedNCT02088684
What this trial is testing

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 70
Post-approval studies (Phase 4)Study completedNCT02445586
What this trial is testing

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 52
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Testing effectiveness (Phase 2)Study completedNCT00238290
What this trial is testing

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Swiss Cancer Institute 13
Testing effectiveness (Phase 2)Ended earlyNCT00777335
What this trial is testing

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Translational Research in Oncology 4
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Study completedNCT00371345
What this trial is testing

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Testing effectiveness (Phase 2)Study completedNCT01105312
What this trial is testing

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 28
Load More Results